But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ApexOnco Front Page
Recent articles
2026’s first big oncology buyout is here.
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.